High genomic instability predicts survival in metastatic high-risk neuroblastoma

Neoplasia (United States)

Volumn 14, Issue 9, 2012, Pages 823-832

  Stigliani, Sara ^a   Coco, Simona ^a   Moretti, Stefano ^b,c   Oberthuer, Andrè ^d   Fischer, Mattias ^d   Theissen, Jessica ^d   Gallo, Fabio ^a   Garaventa, Alberto ^e   Berthold, Frank ^d   Bonassi, Stefano ^f   Tonini Dr , Gian Paolo ^a   Scaruffi, Paola ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Centre National de la Recherche Scientifique   (France)

^c UNIVERSITÉ PARIS DAUPHINE   (France)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e G GASLINI INSTITUTE   (Italy)

^f IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; BETA SECRETASE 1; CELLUBREVIN; MITOFUSIN 2; PROTEIN CDC42; PROTEIN MSH2; RAB PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROUNDABOUT RECEPTOR; SHAW POTASSIUM CHANNEL; VASCULOTROPIN B;

ARTICLE; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE REGULATION; CHILD; CHROMOSOMAL INSTABILITY; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DISEASE COURSE; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MYCN ONCOGENE; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE C MYB; PRESCHOOL CHILD; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 84866635530     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121114     Document Type: Article

References (49)

1. Maris JM, Hogarty MD, Bagatell R, and Cohn SL (2007). Neuroblastoma. Lancet 369, 2106-2120.
2. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, and Machin D (2008). European Neuroblastoma Study Group, and Children's Cancer and Leukaemia Group High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 9, 247-256.
3. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, and Villablanca JG (2009). Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group Study. J Clin Oncol 27, 1007-1013.
4. Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, et al. (2010). Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol 28, 2331-2338.
5. Ora I and Eggert A (2011). Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol 21, 217-228.
6. Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, and Yokoyama T (2004). Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int 20, 33-38.
7. Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, Hanada R, Yamamoto K, Hayashi Y, and Aburatani H (2004). Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer 40, 120-132.
8. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, et al. (2004). Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 64, 6883-6891.
9. Mosse YP, Greshock J, Weber BL, and Maris JM (2005). Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era. Cancer Lett 228, 83-90.
10. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S, et al. (2005). Expression profiling using a tumorspecific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7, 337-350.
11. Scaruffi P, Valent A, Schramm A, Astrahantseff K, Eggert A, and Tonini GP (2005). Application of microarray-based technology to neuroblastoma. Cancer Lett 228, 13-20.
12. Chen Y and Stallings RL (2007). Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67, 976-983.
13. Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, and Brors B (2007). Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. BMC Cancer 7, 89.
14. Bilke S, Chen QR, Wei JS, and Khan J (2008). Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification. Clin Cancer Res 14, 5540-5547.
15. Scaruffi P, Stigliani S, Moretti S, Coco S, De Vecchi C, Valdora F, Garaventa A, Bonassi S, and Tonini GP (2009). Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 9, 441.
16. Spitz R, Betts DR, Simon T, Boensch M, Oestreich J, Niggli FK, Ernestus K, Berthold F, and Hero B (2006). Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma. Cancer Genet Cytogenet 167, 51-56.
17. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, and Berthold F (2006). Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 45, 1130-1142.
18. Vermeulen J, De Preter K, Laureys G, Speleman F, and Vandesompele J (2009). 59-Gene prognostic signature sub-stratifies high-risk neuroblastoma patients. Lancet Oncol 10, 1030.
19. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, et al. (2009). Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 10, 663-671.
20. Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Benard J, Bown N, Combaret V, Couturier J, Defferrari R, et al. (2011). A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 17, 792-804.
21. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, et al. (2009). Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27, 1026-1033.
22. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, and Hedborg F (1993). Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11, 1466-1477.
23. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, et al. (2006). Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24, 5070-5078.
24. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, and Roald B (1999). Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86, 349-363.
25. Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, and Tonini GP (2007). Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet 177, 20-29.
26. Coco S, Theissen J, Scaruffi P, Stigliani S, Moretti S, Oberthuer A, Valdora F, Fischer M, Gallo F, Hero B, et al. (2012). Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. Int J Cancer 131, 1591-1600.
27. Fisher RA (1935). The logic of inductive inference. J R Stat Soc 98, 39-54.
28. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, et al. (2010). Prognostic impact of gene expressionbased classification for neuroblastoma. J Clin Oncol 28, 3506-3515.
29. Griner PF, Mayewski RJ, Mushlin AI, and Greenland P (1981). Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med 94, 557-592.
30. Huang W, Brad T, Sherman BT, and Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.
31. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, et al. (2005). Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353, 2243-2253.
32. Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, Abrahamsson J, Kogner P, and Martinsson T (2010). High-risk neuroblastoma tumors with 11qdeletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 107, 4323-4328.
33. Spitz R, Hero B, Ernestus K, and Berthold F (2003). Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 9, 4835-4840.
34. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, Schramm A, Eggert A, Mestdagh P, De Preter K, Vandesompele J, et al. (2010). Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11qneuroblastoma. Clin Cancer Res 16, 2971-2978.
35. Valentijin LJ, Koppen A, van Asperen R, Root HA, Haneveld F, and Versteeg R (2005). Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res 65, 3136-3145.
36. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, Alcock L, Mestdagh P, Vandesompele J, Speleman F, et al. (2009). Widespread dysregulation of miRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 4, e7850.
37. Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, et al. (2001). Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med Pediatr Oncol 36, 5-10.
38. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, and Vogelstein B (1998). Mutations of mitotic checkpoint genes in human cancers. Nature 392, 300-303.
39. Colicelli J (2004). Human RAS superfamily proteins and related GTPases. Sci STKE 250, RE13.
40. Sahai E, Olson MF, and Marshall CJ (2001). Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 20, 755-766.
41. Clark EA, King WG, Brugge JS, Symons M, and Hynes RO (1998). Integrinmediated signals regulated by members of the rho family of GTPases. J Cell Biol 142, 573-586.
42. Antoine-Bertrand J, Villemure JF, and Lamarche-Vane N (2011). Implication of rho GTPases in neurodegenerative diseases. Curr Drug Targets 12, 1202-1215.
43. Bellanger J, Lazaro J, Diriong S, Fernandez A, Lamb N, and Debant A (1998). The two guanine nucleotide exchange factor domains of Trio link the Rac1 and the RhoA pathways in vivo. Oncogene 16, 147-152.
44. Blangy A, Vignal E, Schmidt S, Debant A, Gauthier-Rouvière C, and Fort P (2000). TrioGEF1 controls Rac- and Cdc42-dependent cell structures through the direct activation of RhoG. J Cell Sci 113, 729-739.
45. Estrach S, Schmidt S, Diriong S, Penna A, Blangy A, Fort P, and Debant A (2002). The human Rho-GEF trio and its target GTPase RhoG are involved in the NGF pathway, leading to neurite outgrowth. Curr Biol 12, 307-312.
46. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, et al. (2012). Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589-593.
47. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, and Himelstein BP (2000). High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6, 1900-1908.
48. Cavallaro U and Christofori G (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4, 118-132.
49. Chen QR, Song YK, Yu LR, Wei JS, Chung JY, Hewitt SM, Veenstra TD, and Khan J (2010). Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma. J Proteome Res 9, 373-382.